A targeted cancer therapy from AstraZeneca’s alliance with Daiichi Sankyo is now FDA approved to treat certain cases of advanced breast cancer, giving the British pharmaceutical giant another ...

A new European survey sponsored by AstraZeneca (AZ) and Daiichi Sankyo has revealed widespread misconceptions about breast cancer and metastatic cases of the disease. The online questionnaire gathered ...

Aditya Bardia, MD, MPH, FASCO, medical oncologist, UCLA Health, discusses findings from the TROPION-Breast01 study on ...

Daiichi Sankyo shares rose sharply after the U.S. Food and Drug Administration approved its breast cancer drug Datroway. Shares were recently 8.7% higher at 4,437 yen, equivalent to $28.39 ...

HER2-negative breast cancer. Datroway, a specifically engineered TROP2-directed antibody drug conjugate or ADC, was discovered by Daiichi Sankyo, and is being jointly developed and commercialised ...

The trial showed an ORR of 62.6% for Enhertu compared to 34.4% for chemotherapy in HER2-low and HER2-ultralow metastatic breast cancer ... milestone payment to Daiichi Sankyo.

Approval of Enhertu marks the first HER2-directed therapy indicated for adults with unresectable or metastatic HR-positive, HER2-low, or HER2-ultralow metastatic breast cancer. The FDA has approved ...

The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...

AstraZeneca and Daiichi Sankyo won U.S. approval for a novel breast cancer treatment, a milestone in the companies’ efforts to turn the medicine into a widely used blockbuster. The Food and Drug ...

AstraZeneca (AZ) and Daiichi Sankyo’s Datroway (datopotamab deruxtecan-dlnk) has been approved by the US Food and Drug Administration (FDA) to treat a subset of breast cancer patients. The ...